BAB V KESIMPULAN DAN SARAN
5.2. Saran
1. Pada penderita disfungsi jantung perlu dilakukan pemeriksaan NT-proBNP untuk menilai tingkat keparahan klinis dan stratifikasi resiko sehingga penatalaksanaannya menjadi lebih optimal
2. Perlu dilakukan penelitian lebih lanjut dengan subyek yang lebih besar dan kelompok kontrol disertai dengan penilaian fungsi ventrikel kiri pada penderita disfungsi jantung
3. Perlunya penelitian tentang NT-proBNP yang dihubungkan dengan berbagai kondisi klinis lainnya seperti gagal ginjal dan diabetes mellitus.
DAFTAR PUSTAKA
1. Francis GS, Gassler JP, Sonnenblick EH. Pathophysiology and Diagnosis of Heart Failure. In: Fusler V, Alexander RW, O’Rourke RA (ed). The Heart 2005. 10th ed; 1: 655-85
2. Wikipedia. Heart Failure. Available from http://en.wikipedia.org/wiki/Heart Failure. 3. Stancheva N, Tisheva S, Jordanova V, et al. NT Pro BNP and HRV and Outcome
in Patients with Heart Failure with Reduced vs Preserved Systolic Function. Journal of IMAB ; 1 : 89-94.
4. Hermann M, Muller S, Kindermann I, et al. Plasma B vitamins and their relation to the severity of chronic heart failure. Am J Clin Nutr 2007;85: 117-23.
5. Levy D, Kenchaiah, Larson MG, Benjamin EJ, Kupka MJ, Kalon KL, Murabito JM, Vasan RS. Long term Trends in the incidence and Survival; with Heart Failure. N Engl J Med 2002;347:1397-1402
6. Hoobs FDR, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre JE. Reliability of N-Terminal Pro-Brain Natriuretic Peptide Assay in Diagnosis of Heart Failure: Cohort Study in Representative and High Risk Community Population. BMJ 2002;324:1498-1502.
7. Kalim H, Soerianata S, Karo-karo S, Idham I. Pedoman Tatalaksana Sindroma Koroner Akut. Dalam: Pedoman Tatalaksana Penyakit Kardiovaskular di Indonesia. PERKI 2003;333-92.
8. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571-9
9. Gremmeler B, Kunert M, Schleiting H, et al. Relation between-terminal pro-brain natriuretic peptide values invasively measured left ventricular hemodynamic indices. Exp Clin Cardiol2003 ; 8: 91-94.
11. Cardarelli R, Lumicao TG. B-type natriuretic Peptide: A Review of its diagnostic, prognostic and therapeutic monitoring value in heart failure for primary care physician. J Am Board Fam Pract 2003;16:327-33.
12. Institute for Clinical System Improvement Technology Assessment Report: B-type Natriuretic Peptide (BNP) for the Diagnosis and Management of Congestive Heart Failure. 2005 August. Accessed Aug 14, 2009. Available at URL address: http://www.icsi.org/index.asp
13. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75
14. de Denus S, Pharand C, Williamson DR. Brain natriuretic peptide in the management of heart failure. The versatile neurohormone. Chest 2004;125:652-68.
15. Suryaatmadja M. Perkembangan terkini B-type Natriuretic Peptide (BNP) petanda biokimia gagal jantung. Dalam: Suryaatmadja M, editor. Pendidikan berkesinambungan patologi klinik 2004. Jakarta. Departemen Patologi Klinik FK UI. 2004:157-71.
16. Institute for Clinical System Improvement. Health care guidelines: Heart Failure in adults. Updated 2004 Feb. Accessed Aug 14, 2009. Available at URL address: http://www.icsi.org/index.asp
17. Krauser DG, Lloyd-Jones DM, Chae CU, et al. Effect of Body Mass Index on Natriuretic Peptide Levels in Patients with Acute Congestive Heart Failure: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 2005;149:744-50.
18. Anwaruddin S, Llyod-Jones DM, Baggish A, et al. Renal function, Congestive Heart Failure and Aminoterminal pro-brain Natriuretic Peptide Measurement: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006;47:91-7.
19. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8
20. Cowie MR, Jourdain P, Maisel A, et al. Clinical application of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003;24:1710-8
21. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82
22. Wiviott SD, Cannon CP, Morrow DA et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non ST elevation myocardial infarction. A TACTICS-TIMI 18 substudy. Circulation 2004;109:580-6 23. Felker GM, Peterson JW, Mark DB. Natriuretic peptides in the diagnosis and
management of heart failure. CMAJ 2006; 175(6): 611-7
24. Mukoyama M, Nakao K, Saito Y, et al. Increase Human Brain Natriuretic Peptide in Congestive Heart Failure. N Engl J Med 1990;323:757-8.
25. Januzzi JL, Van Kimmenade R, Lainchbury J, Bayes-Genis A, Pinto Y, Richards AM. NT-proBNP testing for diagnosis and short term prognosis in acute congestive heart failure: An international pooled analysis of 1256 patients – the International Collaborative of NT-proBNP (ICON) study. Eur Heart J 2006;27(3):330-7
26. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure. European Society of Cardiology. Guidelines for the Diagnosis and Treatment of Chronic Heart Failure. European Heart J 2001;22:1527-60
27. Richards AM, Nicholls MG, Yandle TG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedulin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97:1921-9
28. Bulwer BE, Shamshad F, Solomon SD. Clinical Utility of Echocardiography. In: Solomon SD (ed). Essential Echocardiography. 1st ed. Humana Press, New Jersey. 2007. 71-8
30. Mukoyama M, Nakao K, Saito Y, et al. Increase Human Brain Natriuretic Peptide in Congestive Heart Failure. N Engl J Med 1990;323:757-8.
31. Braunwald E. Heart Failure and Cor Pulmonale. In: Kasper DI, Fauci AS, Longo DL (ed). Harrison’s Principles of Internal Medicine. 2005. 16th ed:1367-77.
32. Jackson G, Gibbs CR, Davies MK, Lip GYH. ABS of Heart Failure: Pathophysiology. BMJ 2000;320:167-70.
33. Fischer C, et al. NT proBNP Predict Prognosis in Patient with Chronic Heart Failure. Heart 2003;89:879-81
34. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the proBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2004;47:91-7
35. Mayoclinic. Heart Failure. Available from: http://www.mayoclinic.com/ health/ Heartfailure/DSooo61/dsection7
36. Medline Plus. Heart Failure. Available from: http://www.nlm.nih.gov/ medlineplus/ency/article/00158.htm
37. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guidelines Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. A Report of the American College of Cardiology / American Heart Association Task Force on Practical Guidelines (Writing Committee to Update the 2001 Guidelines for Evaluation and Management of Heart Failure). Circulation 2005;112:e154-e235. 38. Doughty RN, White HD. Epidemiology of Heart Failure. In: Baliga RR, Pitt B,
GIvertz MM, (ed). Management of Heart Failure. Springerlink. 2008. 1st ed. 1-12. 39. Jessup M, Brozena S. Medical Progress: Heart Failure. N Engl J Med
2003;348:2007-18.
40. Betti I, Castelli G, Barchielli A, et al. The Role of N-terminal PRO- Brain Natriuretic Peptide and Echocardiography for Screening Asymptomatic Left Ventricular Dysfunction in a Population at High Risk for Heart Failure. The PROBE-HF Study. Journal of Cardiac Failure2009; 15 (5): 377-384.
41. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic Peptide in Cardivascular Disease. Lancet 2003;362:316-22.
42. Hall C. Essential biochemistry and physiology of NT-proBNP. Eur J Heart Fail 2004;6:257-60.
43. Figal DA, Domingo M, Casas T, et al. Usefulness of clinical and NT-pro BNP Monitoring for prognostic guidance in destabilized heart failure outpatients. European Heart Journal 2008: 1-8.
44. Apple FS, Panteghini M, Ravkilde J, et al. Quality specifications for B-type natriuretic peptide assays. Clinical Chemistry 2005;51:486-93.
45. Talwar S, Squire IB, Downi PF, Davies JE, Ng LL. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin-1 raised in unstable angina. Heart 2000;84:421-4.
46. Choi EY, Kwon HM, Yoon YW, Kim D, Kim HS. Assessment of extent of myocardial ischemia in patients with non-ST elevation acute coronary syndrome using serum B-type natriuretic peptide level. Yonsei Med J 2004;45:255-62.
47. Goetze JP, Christoffersen C, Perko M, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003;17:1105-7
48. Pemberton CJ, Yandle TG, Rademaker MT, Charles CJ, Aitken GD, Espiner EA. Amino-terminal proBNP in ovine plasma: evidence for enhanced secretion in response to cardiac overload. Am J Physiol Heart Circ Physiol 1998;275:1200-8 49. Bulwer BE, Shamshad F, Solomon SD. Clinical Utility of Echocardiography. In:
Solomon SD (ed). Essential Echocardiography. 1st ed. Humana Press, New Jersey. 2007. 71-8
LEMBAR PENJELASAN KEPADA CALON SUBYEK PENELITIAN
Selama pagi/siang Bapak/Ibu, pada hari ini, saya Dr. Faisal, saat ini sedang menjalani pendidikan program dokter spesialis penyakit dalam di Departemen Ilmu Penyakit Dalam FK USU akan melakukan pengambilan sampel darah untuk penelitian yang berjudul Nilai NT-proBNP Penderita Disfungsi sistolik dan diastolik. Penelitian ini bertujuan untuk mengetahui apakah nilai NT-proBNP mempunyai hubungan dengan tingkat keparahan disfungsi jantung. Dengan mengetahui nilai NT-proBNP ini pada disfungsi jantung, maka dapat digunakan dalam penatalaksanaan disfungsi jantungnya.
Bapak/Ibu, pengambilan sampel darah dilakukan oleh petugas laboratorium pada daerah pembuluh darah lengan atas (v mediana cubiti) sebanyak 3 ml dimana sebelumnya dilakukan sterilisasi pada daerah yang akan diambil darahnya. Kemudian sampel akan di kirim ke laboratorium dan akan di nilai kadarnya. Pengambilan darah ini dilakukan seaman mungkin oleh tenaga yang ahli sehingga tidak menimbulkan resiko saat pengambilannya. Seluruh pemeriksaan yang dilakukan pada Bapak/Ibu tidak dipungut biaya.
Bila ada pertanyaan dapat menghubungi saya : Nama : Dr. Faisal
Alamat : Komplek Tasbih Blok A No. 15 Medan Telp : (061) 76868383 / 0813 6014 0084
LEMBAR PERSETUJUAN SUBYEK PENELITIAN
Saya yang bertandatangan d ibawah ini :
Nama : ………
Alamat : ………
Umur : ………
Jenis Kelamin : ………
Setelah mendapat penjelasan dari peneliti tentang kebaikan dan keburukan prosedur penelitian ini, menyatakan setuju untuk ikut dalam penelitian tentang Nilai NT-proBNP Penderita Disfungsi Sistolik dan Diastolik. Demikianklah surat pernyataan setuju ikut dalam penelitian ini saya buat untuk dapat dipergunakan seperlunya. Medan,………..………….2010